Applied Molecular Transport Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to ...
10 6월 2020 - 5:05AM
Applied Molecular Transport (Nasdaq: AMTI), a clinical-stage
biopharmaceutical company, today announced the closing of its
initial public offering of 12,650,000 shares of its common stock,
which includes the exercise in full by the underwriters of their
option to purchase up to 1,650,000 additional shares, at a public
offering price of $14.00 per share. The aggregate total gross
proceeds to AMT from the offering were $177.1 million, before
deducting underwriting discounts and commissions and other offering
expenses. All of the shares in the offering were offered by AMT.
AMT’s common stock began trading on the Nasdaq Global Select Market
on June 5, 2020, under the ticker symbol “AMTI.”
BofA Securities, Jefferies and SVB Leerink acted
as joint book-running managers for this offering.
Registration statements relating to the offering
of these securities have been filed with the Securities and
Exchange Commission and became effective on June 4, 2020. The
offering was made only by means of a prospectus. Copies of the
final prospectus relating to this offering may be obtained from:
BofA Securities, NC1-004-03-43, 200 North College Street, 3rd
floor, Charlotte, NC 28255-0001, Attention: Prospectus Department,
or by email at dg.prospectus_requests@bofa.com; Jefferies LLC,
Attention: Equity Syndicate Prospectus Department, 520 Madison
Avenue, 2nd Floor, New York, NY 10022, or by telephone at (877)
821-7388, or by email at prospectus_department@Jefferies.com; or
SVB Leerink LLC, Attention: Syndicate Department, One Federal
Street, 37th Floor, Boston, MA 02110, or by telephone at (800)
808-7525, ext. 6218, or by email
at syndicate@svbleerink.com.
This press release shall not constitute an offer
to sell or the solicitation of an offer to buy, nor shall there be
any offer or sale of these securities in any state or jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of
such state or jurisdiction.
About Applied Molecular Transport
Inc.
Applied Molecular Transport Inc. is a
clinical-stage biopharmaceutical company leveraging its proprietary
technology platform to design and develop a pipeline of novel oral
biologic product candidates to treat autoimmune, inflammatory,
metabolic, and other diseases. AMT’s proprietary technology
platform allows it to exploit existing natural cellular trafficking
pathways to facilitate the active transport of therapeutic payloads
across the intestinal epithelium (IE) barrier. Active transport is
an efficient mechanism that uses the cell’s own machinery to
transport materials across the IE barrier. AMT believes that its
ability to exploit this mechanism is a key differentiator of its
approach. AMT is developing oral biologic product candidates in
patient-friendly tablet and capsule forms that are designed for
either targeting local gastrointestinal (GI) tissue or entering
systemic circulation to precisely address the relevant biology of a
disease. AMT is building a portfolio of oral product candidates
based on its technology platform including its lead product
candidate, AMT-101, an oral GI-selective interleukin 10 that has
completed a Phase 1b clinical trial in patients with ulcerative
colitis (UC). AMT further plans to initiate Phase 2 clinical trials
of AMT-101 in UC and related inflammatory indications. AMT’s
technology platform enables it to design and develop various oral
biologic therapeutic modalities, such as peptides, proteins,
full-length antibodies, antibody fragments, and RNA therapeutics,
with potentially significant advantages over existing marketed and
development-stage drugs.
Contacts: Sylvia WheelerPrincipal, Wheelhouse Life Science
Advisorsswheeler@wheelhouselsa.com
Alexandra SantosSenior Partner, Wheelhouse Life Science
Advisorsasantos@wheelhouselsa.com
Applied Molecular Transp... (NASDAQ:AMTI)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Applied Molecular Transp... (NASDAQ:AMTI)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024